Cartesian Therapeutics' (RNAC) Buy Rating Reaffirmed at HC W

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set […]

Related Keywords

United States , American , Timothya Springer , Hall Laurie , Leerink Partnrs , Cartesian Therapeutics Inc , Sg Americas Securities , American International Group Inc , Delphi Financial Group Inc , Needham Company , Cartesian Therapeutics , Free Report , Get Free Report , Director Timothy , Lauriej Trustee , International Group , Financial Markets , Delphi Financial Group , Cartesian Therapeutics Daily ,